Vaxcyte Inc (PCVX) reported disappointing financial results for the third quarter of fiscal 2025. The company recorded an earnings per share (EPS) of $-1.56, falling short of Wall Street's consensus estimate of $-1.29 by $0.27. Revenue remained at $0.0 billion, matching analyst expectations but offering little in terms of growth.
The company, headquartered in San Carlos, California, focuses on developing vaccines for infectious diseases. Its current pipeline includes VAX-31, a 31-valent pneumococcal conjugate vaccine candidate, which is advancing to a Phase III adult clinical program while also being evaluated in a Phase II infant clinical program. Vaxcyte's other candidates include VAX-24, VAX-A1, VAX-PG, and VAX-GI, each targeting various infectious diseases.
Vaxcyte plans to host an earnings conference call to discuss these results and provide further insights into its business performance. Investors may wish to review the full earnings release and listen to management's commentary for a comprehensive understanding of the quarter's performance and future outlook.
As of November 8, 2025, Vaxcyte holds a market cap of $5,430.65 and an EPS (TTM) of -4.11. Upcoming earnings are anticipated on May 4, 2026, with an EPS estimate of -1.3541 and revenue also expected at $0.0 billion.